I don't think you'll ever see a drug data PR without the use of "generally" with respect to side effects. It's a nice blanket term. No hcv drug is going to have no side effects. I wouldn't think too much of it in the context of the PR.
I listened to the VRUS presentation at the Goldman Sachs Healthcare Conference on 6/9/09 (http://investor.pharmasset.com/events.cfm ) and they give a very brief mention of the safety issues seen in the Phase 1a trial of PSI-7851. I can't make out what the presenter is saying but it's just past the 7 minute mark if anyone wants to try and decipher. It sounds like "ecd pads" or something but I have no idea.
Market Data 
Markets 
AI
